Research organization Italbiotec assists businesses in securing financial backing for their research and development projects through various funding and grant programs.
In a bold move to bolster its position as a leading player in the life sciences, agro-food, and bioeconomy sectors, Italbiotec, Italy's largest non-profit organisation dedicated to biotechnology development, has unveiled an ambitious growth strategy for the next five years.
The strategy, centred around strengthening international expansion, pursuing acquisitions, and advancing technology development, aims to tap into strategic bioeconomy markets and expand the ecosystem of sustainable innovation.
At the heart of this strategy is international expansion. Italbiotec plans to broaden its global footprint by forming and consolidating strategic alliances and partnerships with international organisations, research institutions, and companies. This approach will help facilitate technology transfer, collaborative R&D, and market access beyond Italy.
The consortium seeks to grow through targeted acquisitions and integration of complementary entities or projects that align with its mission in biotechnologies, agro-food innovation, and life sciences. This also involves partnering with both public and private entities to consolidate expertise and technological assets.
Italbiotec emphasizes investment in cutting-edge technology platforms and applied research to maintain leadership in biotechnology innovation. This includes support for industrial research and technology transfer labs (like T3Lab), with a focus on sustainable solutions in biotechnology and agro-food sectors.
The strategy also involves leveraging AI for biotech process digitalization. To this end, Italbiotec expects to acquire specialized R&D entities to bolster its technological capabilities.
Diego Bosco, CEO of Italbiotec, is optimistic about the future. He expects 2025 to be a year of growth, driven by strengthening international activities, new strategic partnerships, and investments in R&D, sustainability, digitalization, and human resources. The plan spans over the next five years, with Italbiotec anticipating double-digit growth in 2025, primarily due to increased technology transfer activities, consolidation of academic and industrial partnerships, and a strengthened European position.
Based in Milan, Italy, Italbiotec operates as a benefit corporation, with a commitment to creating a positive impact on society and the environment. With its ambitious growth strategy, Italbiotec is poised to make significant strides in the biotechnology and related sectors, both in Italy and globally.
The ambitious strategy of Italbiotec, aimed at expanding over the next five years, includes pursuing acquisitions to integrate complementary entities, particularly those aligned with biotechnologies, agro-food innovation, and life sciences. This growth strategy also involves strengthening international expansion by forming alliances with international organisations, research institutions, and companies for technology transfer, collaborative R&D, and market access. Lastly, Italbiotec is planning to advance technology development by leveraging AI for biotech process digitalization and by acquiring specialized R&D entities in finance to bolster its technological capabilities.
